By Business Wire, September 25, 2013, 04:05:00 PM EDT
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced today that the
Company will host an investor reception and webcast to discuss the
development of its lead drug candidate, ganetespib, for the treatment of
lung and breast cancers at the 2013 European Cancer Congress
(ECCO-ESMO-ESTRO), which is taking place September 27 - October 1 in
The investor event will take place on Saturday, September 28, 2013, from
6:30 p.m. to 8:30 p.m. CEST (12:30 p.m. to 2:30 p.m. EDT), and will
include discussion of upcoming milestones for the remainder of the year.
The reception will be webcast beginning at 7:00 p.m. CEST (1:00 p.m.
EDT), which along with an accompanying slide presentation and replay of
the event, will be available on the home page of the Company's website, www.syntapharma.com.
Ganetespib, an investigational drug candidate, is a selective inhibitor
of heat shock protein 90 (Hsp90), a molecular chaperone which controls
the folding and activation of a number of client proteins that drive
tumor development and progression. Many solid and hematologic tumors are
dependent on Hsp90 client proteins including proteins involved in
"oncogene addiction" (ALK, HER2, mutant BRAF and EGFR, androgen
receptor, estrogen receptor, JAK2); proteins involved in resistance to
chemotherapy and radiation therapy (ATR, BCL2, BRCA1/2, CDK1/4, CHK1,
survivin, and WEE1); proteins involved in angiogenesis (HIF-1alpha,
VEGFR, PDFGR, and VEGF); and proteins involved in metastasis (MET, RAF,
AKT, MMPs, HIF-1alpha, and IGF-1R). In preclinical models, inhibition of
Hsp90 by ganetespib results in the inactivation, destabilization, and
eventual degradation of these cancer-promoting proteins. Ganetespib is
being evaluated in trials in lung cancer, breast cancer, and other tumor
types. The most common adverse event seen to date has been transient,
mild or moderate diarrhea, which has been manageable with standard
supportive care. Information on these trials can be found at www.clinicaltrials.gov.
Ganetespib has received Fast Track designation from FDA for second-line
treatment of non-small cell lung adenocarcinoma in combination with
About the GALAXY Program
The GALAXY (Ganetespib Assessment in Lung cancer with docetaXel) program
consists of two randomized trials comparing the combination of
ganetespib and docetaxel versus docetaxel alone in patients with Stage
IIIB/IV NSCLC who have received one prior systemic therapy: a
300-patient Phase 2b/3 trial (GALAXY-1) to determine the patient
population most likely to derive benefit from ganetespib, and a
500-patient confirmatory Phase 3 trial (GALAXY-2). More information
about the GALAXY trials can be found at www.clinicaltrials.gov
(NCT01348126 and NCT01798485).
About the ENCHANT-1 Clinical Trial
ENCHANT-1 is a proof-of-concept, "window-of-opportunity" trial designed
to evaluate single-agent ganetespib safety and clinical activity in
locally advanced or first-line metastatic HER2-positive and
triple-negative breast cancer. The trial will also evaluate the
combination of ganetespib with paclitaxel. More information about this
trial can be found at www.clinicaltrials.gov
About Lung Cancer
Lung cancer is the leading cause of cancer-related death in the world,
accounting for nearly 1.4 million deaths in 2008, according to the World
Health Organization. The five-year survival rate for this disease is
approximately 16%; over half of people with lung cancer die within one
year of being diagnosed. In the U.S., the American Cancer Society
estimates that 228,000 cases of lung cancer will be diagnosed in 2013.
Non-small cell adenocarcinoma comprises about 40% of all lung cancer.
About Breast Cancer
Breast cancer is the most frequent cancer in women, accounting for
458,000 deaths worldwide in 2008, according to the World Health
Organization. In the U.S., the American Cancer Society estimates that
about 297,000 cases of breast cancer will be diagnosed in 2013. Breast
cancer is often characterized in the context of three biomarkers: ER/PR
positive, HER2-positive, or negative for all three (triple-negative).
Standard treatment for the first two categories includes therapies
targeting hormonal or HER2 signaling pathways. There are no established
targeted therapies for patients with triple-negative disease, which
accounts for approximately 15% of all breast cancer and is associated
with poor patient prognosis.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to
extend and enhance the lives of patients with severe medical conditions,
including cancer and chronic inflammatory diseases. Synta has a unique
chemical compound library, an integrated discovery engine, and a diverse
pipeline of clinical- and preclinical-stage drug candidates with
distinct mechanisms of action and novel chemical structures. All Synta
drug candidates were invented by Synta scientists using our compound
library and discovery capabilities. For more information, please visit www.syntapharma.com.
Source: Synta Pharmaceuticals Corp.